Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
201.91
+0.28 (+0.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
46
47
Next >
Stock Market Rallies Amid Huge Earnings, Fed Rate Hike, Inflation Data: Weekly Review
July 28, 2023
Despite Thursday's downside reversal, the major indexes had a solid advance.
Via
Investor's Business Daily
Biogen (NASDAQ: BIIB) Acquires Reata (NASDAQ: RETA) to Boost its Neurological Therapeutics Portfolio, Including SKYCLARYS®
July 28, 2023
Reata's Acquisition to Propel Biogen's Growth Strategy Biogen Inc. (NASDAQ: BIIB) and Reata Pharmaceuticals, Inc. (NASDAQ: RETA) have announced a
Via
Spotlight Growth
Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals
July 28, 2023
Via
Benzinga
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
July 27, 2023
Biogen shares have stagnated in recent years, but the company has a plan to change that.
Via
The Motley Fool
Analyst Ratings for Biogen
July 26, 2023
Via
Benzinga
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
July 28, 2023
Earlier today, Biogen Inc (NASDAQ: BIIB) agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of
Via
Benzinga
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
July 28, 2023
Reata Pharmaceuticals (RETA) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (BIIB).
Via
InvestorPlace
Biogen Announces $7.3 Billion Acquisition Of Reata Pharmaceuticals
July 28, 2023
Reata stock surged more than 50% on the news.
Via
Investor's Business Daily
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
July 28, 2023
Biogen Inc (NASDAQ: BIIB) has agreed to acquire Reata Pharmaceuticals Inc (NASDAQ: RETA) for $172.50 per share in cash, reflecting an enterprise value of
Via
Benzinga
Biogen to Acquire Reata Pharmaceuticals
July 28, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biogen (BIIB) Q2 2023 Earnings Call Transcript
July 25, 2023
BIIB earnings call for the period ending June 30, 2023.
Via
The Motley Fool
Biogen Inc. Tops Q2 Earnings And Revenue Estimates
July 25, 2023
Biogen Inc. came out with quarterly earnings of $4.02 per share.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
July 27, 2023
Via
Benzinga
Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?
July 27, 2023
--News Direct--
Via
News Direct
Exposures
Product Safety
Better Big Biotech Buy: Vertex vs. Biogen
July 24, 2023
These companies have a track record of billion-dollar earnings.
Via
The Motley Fool
Biogen Earnings Preview
July 24, 2023
Via
Benzinga
Biogen Unusual Options Activity
July 21, 2023
Via
Benzinga
(BIIB) - Analyzing Biogen's Short Interest
July 20, 2023
Via
Benzinga
Why Sage Therapeutics Stock Is Tumbling Today
July 26, 2023
A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.
Via
The Motley Fool
Why Biogen Stock Got Sick Today
July 25, 2023
While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light.
Via
The Motley Fool
Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories
July 25, 2023
The Hill Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event
Via
Benzinga
WMT Stock Alert: Is Walmart Really Worth $210?
July 25, 2023
Walmart (WMT) stock is in the news Tuesday as investors react to the latest coverage from Piper Sandler analyst Edward Yruma.
Via
InvestorPlace
MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage
July 25, 2023
Mobileye (MBLY) stock is on the move Tuesday after Morgan Stanley analyst Adam Jonas renewed coverage of the company's shares.
Via
InvestorPlace
Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts
July 25, 2023
Biogen (BIIB) layoffs are on the way as the company seeks further profits with its upcoming Alzheimer's disease drug launch.
Via
InvestorPlace
Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff
July 25, 2023
Biogen Inc (NASDAQ: BIIB) posted Q2 FY23 sales of $2.46 billion, beating the con
Via
Benzinga
Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting'
July 25, 2023
Via
Benzinga
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
July 24, 2023
Analysts expect Biogen to report a a decline in both profits and sales in Q2.
Via
Investor's Business Daily
Goldman Sachs, Charles Schwab And This Healthcare Stock On CNBC's 'Final Trades'
July 21, 2023
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Biogen Inc.
Via
Benzinga
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
July 19, 2023
From
Biogen Inc.
Via
GlobeNewswire
Acumen Soars on Alzheimer's Study...Street Sees It Doubling
July 19, 2023
Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price?
Via
MarketBeat
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.